Excreted urinary glycans Analysis and diagnosis of kidney disease without renal Tissue specimens(Extant) Study -Multicenter Prospective study-

Excreted urinary glycans Analysis and diagnosis of kidney disease without renal Tissue specimens(Extant) Study -Multicenter Prospective study- - Extant Prospective Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033985

Enrollment

400

Registered

2019-01-01

Start date

2019-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with renal biopsy at 16 institutions (Okayama university hospital, Okayama Okayama Saiseikai General Hospital, National Hospital Organization Okayama Medical Center, Kurashiki Central Hospital, Japanese Red Cross Okayama Hospital, Japanese Red Cross Society Himeji Hospital, Cugoku Central Hospital, Hiroshima City Hiroshima Citizens Hospital, Onomichi Municipal Hospital, Kousei General Hospital, Ehime Prefectural Central Hospital, Matsuyama Shimin Hospital, Mitoyo General Hospital, Kagawa Prefectural Central Hospital, Kagawa Rosai Hospital, and Kochi Health Sciences Center) between January 2019 and December 2019.

Exclusion criteria

Exclusion criteria: 1. Patients who decline the entry of this study. 2. Patients who are regarded as inappropriate for joining this study.

Design outcomes

Primary

Measure	Time frame
Clinical performance for differentiating IgA nephropathy from other renal diseases by the combination of urinary glycan profiling and clinical tests (hematuria, proteinuria, serum IgA) (Sensitivity and Specificity)	—

Secondary

Measure	Time frame
1) Clinical performance for differentiating IgA nephropathy from other renal diseases by the combination of urinary glycan profiling and clinical tests (hematuria, proteinuria, serum IgA) (Accuracy and ROC-AUC) 2) Clinical performance for differentiating IgA nephropathy from other renal diseases by urinary glycan profiling (Sensitivity and Specificity) 3) Clinical performance for differentiating IgA nephropathy from other primary glomerular diseases by the combination of urinary glycan profiling and clinical tests (hematuria, proteinuria, serum IgA) (Sensitivity, Specificity, Accuracy, and ROC-AUC) 4) Clinical performance for differentiating the participants with IgA nephropathy from with other renal diseases in 4 subgroups defined by 2 factors, eGFR (>= or <30 mL/min/1.73m2), and proteinuria (>= or <0.5 g/gCr), by the combination of urinary glycan profiling and clinical tests (Sensitivity, Specificity, Accuracy, and ROC-AUC)	—

Measure

Time frame

1) Clinical performance for differentiating IgA nephropathy from other renal diseases by the combination of urinary glycan profiling and clinical tests (hematuria, proteinuria, serum IgA) (Accuracy and ROC-AUC) 2) Clinical performance for differentiating IgA nephropathy from other renal diseases by urinary glycan profiling (Sensitivity and Specificity) 3) Clinical performance for differentiating IgA nephropathy from other primary glomerular diseases by the combination of urinary glycan profiling and clinical tests (hematuria, proteinuria, serum IgA) (Sensitivity, Specificity, Accuracy, and ROC-AUC) 4) Clinical performance for differentiating the participants with IgA nephropathy from with other renal diseases in 4 subgroups defined by 2 factors, eGFR (>= or <30 mL/min/1.73m2), and proteinuria (>= or <0.5 g/gCr), by the combination of urinary glycan profiling and clinical tests (Sensitivity, Specificity, Accuracy, and ROC-AUC)

—

Countries

Japan

Contacts

Public ContactKoki Mise

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of Nephrology, Rheumatology, Endocrinology and Metabolism

kokims-frz@okayama-u.ac.jp086-235-7235

Outcome results